ShareholdingMay 18, 2026, 10:22 AM
AstraZeneca CEO Pascal Soriot Acquires 18,359 Shares from Vested AZPSP
AI Summary
AstraZeneca announced that its Executive Director and Chief Executive Officer, Pascal Soriot, acquired 18,359 ordinary shares on May 14, 2026. This transaction resulted from the vesting of an award under the AstraZeneca Performance Share Plan (AZPSP), which was granted on May 14, 2021. The award vested at 88% after a three-year performance period and a two-year holding period, with shares withheld to cover tax obligations. The fair market value of an ordinary share for tax purposes was 13,766 pence.
Key Highlights
- AstraZeneca CEO Pascal Soriot acquired 18,359 ordinary shares.
- Shares vested under the AstraZeneca Performance Share Plan (AZPSP) on May 14, 2026.
- The AZPSP award was granted on May 14, 2021, with a 3-year performance and 2-year holding period.
- 88% of the AZPSP award vested, with the unvested portion lapsing.
- Fair market value for tax purposes was 13,766 pence per ordinary share.
- The acquisition of shares was for nil consideration.
Price Impact
More from AZN